# INTERFERONS--PROPERTIES, ACTION AND PATIENT PRESCREENING

> **NIH NIH R01** · FORDHAM UNIVERSITY · 1989 · $117,144

## Abstract

Studies will be undertaken to gain further insight into the biological and
biochemical effects of the human interferons so as to further elucidate
their mechanism(s) of action and ascertain how they can best be employed
therapeutically.  One of the proposed aims is to produce polyclonal and
monoclonal antibodies directed against the proteins induced in
interferon-treated cells.  These antibodies will be used to examine the
interferon-treated cells, to ascertain whether the induced proteins
synthesized in response to the different human interferons are structurally
and antigenically related and to determine whether these interferon-induced
proteins play a role in the action of the interferon-induced enzyme
activities.  Methodologies will also be developed and employed which will
allow for a determination of the responsiveness of freshly removed tumor
tissues to the effects of the different human interferons.  This
methodology will use as a measure of responsiveness to the interferons the
ability of the tumor cells to synthesize the interferon-induced proteins.
This measurement will be accomplished by using the antibodies directed
against the interferon-induced proteins to either immunoprecipitate
radioactively-labeled interferon-induced proteins from the
interferon-treated tumor cells or to stain the interferon-treated tumor
cells for the presence of the interferon-induced proteins.  A determination
of the rsponsiveness to the interferons could be made rapidly (in 24 hr)
and would allow clinicians to select patients for interferon therapy that
are capable of responding to the interferon.  The interferons have been
found to differ in their abilities to inhibit the replication of different
viruses.  This comparison will be extended to include other clinically
relevant viruses (e.g., adenovirus and herpes simplex virus) to determine
which of the interferons is best capable of inhibiting the replication of
these viruses.  Purified E. coli-derived Gamma interferon has been shown in
this laboratory to have a lower specific activity than leukocyte-derived
Gamma interferon.  Studies will be undertaken to compare the structural and
biological properties of leukocyte and E. coli-derived Gamma interferons
and to determine whether this observed difference in specific activity is
due to the absence of carbohydrate on the E. coli-derived Gamma interferon.

## Key facts

- **NIH application ID:** 3176839
- **Project number:** 7R01CA038661-07
- **Recipient organization:** FORDHAM UNIVERSITY
- **SAM.gov UEI:** ECESTN2SSVH1
- **Principal Investigator:** Berish Y Rubin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $117,144
- **Award type:** 7
- **Project period:** 1989-09-30 → 1992-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3176839

## Citation

> US National Institutes of Health, RePORTER application 3176839, INTERFERONS--PROPERTIES, ACTION AND PATIENT PRESCREENING (7R01CA038661-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3176839. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*